
(12) **UK Patent Application** (19) **GB** (11) **2 005 538 A**

(21) Application No **7838638**
(22) Date of filing **29 Sep 1978**
(23) Claims filed **29 Sep 1978**
(30) Priority data
(31) **42191/77**
(32) **11 Oct 1977**
(33) **United Kingdom (GB)**
(43) Application published
25 Apr 1979

(51) **INT CL²**
A61K 31/43 31/42
(52) Domestic classification
A5B 180 213 216 21Y J
(56) Documents cited
None

(58) Field of search
A5B

(71) Applicants
**Beecham Group Limited,
Beecham House, Great
West Road, Brentford,
Middlesex, England**

(72) Inventor
Patrick John Crowley

(74) Agents
W. G. Cole

**(54) Compositions containing
amoxycillin trihydrate and
potassium clavulanate**

**(57) A dry unit-dose pharmaceutical
composition suitable for oral
administration comprises 20 mg to**

**1500 mg of amoxycillin trihydrate, 20
mg to 500 mg of potassium
clavulanate and a pharmaceutically
acceptable carrier with the proviso
that the weight ratio of amoxycillin
trihydrate to potassium clavulanate is
from 6:1 to 1:1.**

GB 2 005 538 A

SPECIFICATION Pharmaceutical compositions

The present invention relates to pharmaceutical compositions for oral administration in the treatment of bacterial infections.

5 Amoxycillin and its salts were disclosed in British Patent Specification No. 1241844 as anti- 5
bacterial agents useful in the treatment of gram-negative and gram-positive bacterial infections.
However, certain bacteria are resistant to amoxycillin by virtue of the β -lactamase they produce.
Clavulanate salts were disclosed in British Patent Specification No. 1508977 as β -lactamase inhibitors
capable of enhancing the anti-bacterial effects of penicillins and cephalosporins.

10 We have now found that when amoxycillin trihydrate is formulated in a composition together with 10
potassium clavulanate, the resulting composition has a greater storage life than analogous
compositions in which the potassium clavulanate is replaced by sodium clavulanate or the like or if the
amoxycillin trihydrate is replaced by the sodium amoxycillin. This enhancement of storage stability is
particularly effective when the materials present in the composition are dry, that is essentially water-
15 free, for example as obtained by pre-drying to remove moisture other than the water of crystallisation 15
present in the amoxycillin trihydrate.

Accordingly the present invention provides a dry unit-dose pharmaceutical composition suitable
for oral administration which composition comprises 20 mg to 1500 of amoxycillin trihydrate, 20 mg to
500 mg of potassium clavulanate and a pharmaceutically acceptable carrier with the proviso that the
20 weight ratio of amoxycillin trihydrate to potassium clavulanate is from 6:1 to 1:1. 20

When weights or weight ratios are referred to herein said weights or weight ratios are based on
the weight of parent antibiotic (amoxycillin or clavulanic acid) theoretically available from the
composition.

More suitably the weight ratio of amoxycillin trihydrate to potassium clavulanate is from 5:1 to
25 2:1 for example 5:1, 4:1, 3:1 or 2:1. 25

Preferred weight ratios of amoxycillin trihydrate to potassium clavulanate vary from about 3:1 to
about 2:1 a ratio of about 2:1 being particularly preferred.

In general the oral dosage unit of this invention will contain from 125 mg to 1250 mg of
amoxycillin trihydrate for example it may contain about 225, 250, 290, 435, 500, 580, 870 or 1000
30 mg of amoxycillin trihydrate. 30

In general the oral dosage unit of this invention will contain from 40 to 300 mg of potassium
clavulanate for example it may contain about 50, 60, 75, 100, 120, 125, 150, 200, 240, 250 or 300
mg of potassium clavulanate.

From the foregoing it will be realised that certain preferred compositions of this invention
35 comprise from 80 mg to 600 mg of amoxycillin trihydrate and from 40 mg to 300 mg of potassium 35
clavulanate with the proviso that the weight ratio of amoxycillin trihydrate to potassium clavulanate is
2:1.

Suitable amounts of potassium clavulanate for use in those compositions include the
aforementioned approximately 50, 60, 75, 100, 120, 125, 150, 200, 240, 250 or 300 mgs.

40 The oral dosage unit of this invention may be in the form of a tablet, capsule, syrup powder or 40
granulate for reconstitution presented in a sachet or the like. Shaped forms of the composition such as
tablets or capsules are particularly suitable.

Certain preferred compositions, especially shaped compositions of this invention will contain
about 125—150 mg of amoxycillin trihydrate and about 62.5—75 mg of potassium clavulanate. Other
45 preferred compositions, especially shaped compositions of this invention will contain about 250—300 45
mg of amoxycillin trihydrate and about 125—150 mg of potassium clavulanate.

Such compositions may contain one or more conventional fillers such as microcrystalline
cellulose, lubricants such as magnesium stearate, disintegrants such as sodium starch glycollate or
other similar known agents. In addition such compositions may contain flavouring agents, preservatives,
50 colouring agents and the like. The materials present in such compositions should be water-free and 50
preferably pre-dried.

Other typical agents which may be used in the carrier include microfine cellulose (as a filler),
calcium carbonate or magnesium carbonate (usually light magnesium carbonate) (as fillers), starch (as a
disintegrant) and glycine (as a disintegrant).

55 Tablets according to this invention may be film coated if desired, for example with a coat that 55
delays ingress of moisture. Suitable agents for such film coats include, methacrylic acid methacrylate
co-polymers, and natural resins such as shellac or copal resins or their conventional modifications.

The compositions of this invention show an especially improved storage life if they are packed in
such a manner as that ingress of moisture is prevented. This may be conveniently effected by packing in
60 a screw-capped bottle or some other similar effectively closed container such as a screw top metal 60
cannister.

Thus the present invention further provides a packaged pharmaceutical composition of enhanced
storage stability which comprises a container closed to prevent ingress of moisture and which contains
one or more unit-dose compositions as hereinbefore described.

It is particularly advantageous to include a desiccant within the package.

Thus in a further aspect this invention provides a packaged pharmaceutical composition of enhanced storage stability which comprises a container closed to prevent ingress of moisture and which contains one or more unit-dose compositions as hereinbefore described and a desiccant.

5 Suitable desiccants will be non-toxic and include Silica Gel or crystalline sodium, potassium or calcium aluminosilicate (commonly termed "Molecular Sieves"). Such desiccants may be included in sachets or capsules within the packaging or may be enclosed in a receptacle or separate compartment, for example in the cap or on the floor of the container. 5

10 In yet another aspect of this invention provides a method of prolonging the storage life of a composition as hereinbefore described in a container which comprises storing said composition in an atmosphere maintained dry by the presence of a desiccant in the container. 10

Suitable containers and desiccants are as hereinbefore described.

The dosage form of this invention may be fabricated in the conventional manner, for example by blending and compressing to form tablets, blending and filling into capsules or blending and filling into 15 sachets and the like. 15

Thus this invention provides a process for the preparation of preparing a composition as hereinbefore described which comprises bringing into association the components of said compositions.

20 Suitably the unit-dose compositions when prepared are filled into a container which is then closed to prevent ingress of moisture. 20

It is preferable that the formulation of the composition is carried out in a dry atmosphere, e.g. one containing less than 30% relative humidity and more suitably one containing less than 20% relative humidity.

25 In the following examples, which illustrate the invention, the compositions were formulated under a dry atmosphere. 25

EXAMPLE 1.

Tablets of the following compositions were prepared:

Ingredients	mg per tablet			
Amoxycillin Trihydrate	290	290	580	580
Potassium Clavulanate	60	150	120	300
Colloidal Silica	3.0	3.8	6.0	7.6
Sodium Starch Glycollate (dried)	7.2	8.9	14.4	17.8
Magnesium Stearate	5.0	6.2	10.0	12.4
Microcrystalline Cellulose (Dried) to	436.0	550.0	872.0	1100.0

30 The tablets were prepared by passing the ingredients through a 30 mesh (British Standard) sieve and then blending them. The mix was then compressed in a conventional tablet machine. The tablets were prepared in a batch of about 5000 tablets. 30

The preparation of the tablets was carried out in a dry atmosphere (relative humidity less than 30%).

EXAMPLE 2.

35 Tablets having the same composition as those of Example 1 were also prepared by the following process: the potassium amoxycillin and potassium clavulanate were sieved, blended with a proportion of the disintegrant and lubricant (about $\frac{1}{2}$ of each) and compressed to a uniform density on a tablet machine. The pressed slugs were milled to produce granules of a uniform size and density and the remainder of the ingredients then mixed in. The blend was then compressed to tablets on a conventional 40 tablet machine. The tablets were prepared in a batch of about 5000 tablets. 40

The preparation of the tablets was carried out in a dry atmosphere (relative humidity less than 30%).

EXAMPLE 3.

45 Fifteen of the 290/150 mg tablets of Example 1 were packed in an amber glass bottle and the bottle closed with its metal screw cap to exclude ingress of moisture. Prior to capping a sachet of molecular sieve (sodium aluminosilicate (type 4A) (1.0 g) in a moisture-permeable sachet) was 45

included.

A bottle of 290/60 mg tablets were similarly prepared.

After storage the potencies of the ingredients were found to be as follows:

Strength	Storage Period (months)	Storage Temperature (°C)	Stability (% of initial potency)	
			Trihydrate Amoxycillin	Potassium Clavulanate
290/60	Initial		100	100
	2	20	97	100
		30	99	100
		37	100	98
	4	30	96	101
		37	96	100
290/150	Initial		100	100
	2	30	99	105
		37	99	104

5

Similar capped bottles may be prepared in which the molecular sieve is replaced by silica gel. After further storage the observed potencies for these forms were:

5

Strength	Storage Period (months)	Storage Temp. (°C)	Stability (% initial)	
			Amoxycillin Trihydrate	Potassium Clavulanate
290/60	8	20	99	95
		30	98	90
	12	20	98	95
290/150	4	30	96	102
		37	97	100
	8	20	105	99
		30	101	99
		37	98	95
	12	20	103	101
		30	97	104
		37	95	99

EXAMPLE 4.

A single-dose sachet containing a dry powder to be reconstituted with water before administration may be prepared containing the following:

10

	mg per dose	
Amoxycillin Trihydrate	145	
Potassium Clavulanate	75	
Buffering Agent	10.0	
Flavour	55.0	5
Desiccating Agent	500.0	
Glidant	20.0	
Sugar to	3300.0	

EXAMPLE 5.

10 Tablets of the following compositions were prepared:

10

Ingredient	mg per tablet
Amoxycillin Trihydrate	equivalent to 125 mg of pure free non-hydrated amoxycillin
Potassium Clavulanate	equivalent to 62.5 mg of pure clavulanic acid
Cross-linked polyvinylpyrrolidone (disintegrant)	50.0
Monoammonium Glycrrhizinate (flavour enhancer)	15.0
Flavours	32.5
Magnesium stearate (lubricant)	20.0
Microcrystalline cellulose to	750.0

The tablets were prepared in batches of 2000 by passing the ingredients through a 30 mesh sieve, blending together and compressing on a suitable tablet machine.

15 Fifteen of the above tablets were packed in amber glass bottles and the bottle closed with a metal screw-cap to exclude ingress of moisture. Prior to capping a sachet of molecular sieve (1.0 g) was included.

15

After storage the potencies of the ingredients were found to be as follows:

Storage Period (months)	Storage Temp. (°C)	Stability (% of Initial potency)	
		Amoxycillin trihydrate	Potassium Clavulanate
Initial		100	100
2	37	102	100
4	30	98	100
	37	94	101
8	20	102	96
	30	99	96
	37	92	91

EXAMPLE 6.

20 Tablets of the following composition were prepared:

20

Ingredient	mg/tablet
Amoxicillin Trihydrate	equivalent to 250 mg of pure non-hydrated amoxicillin
Potassium clavulanate	equivalent to 125 mg of pure clavulanic acid
Microfine Cellulose	100
Sodium Starch Glycolate	15
Magnesium Stearate	8
Microcrystalline Cellulose to	765

The tablets were prepared as follows: The active ingredients were passed through a 16 Mesh screen and blended with the microfine cellulose, a portion of the microcrystalline cellulose and a portion of the magnesium stearate. The mix was compressed to a uniform density on a suitable tablet machine.

- 5 The pressed slugs were milled to produce granules of uniform size and density and the remainder of the ingredients were then incorporated. The mix was blended and compressed to tablets on a suitable machine. 5

Storage Period (Months)	Storage Temp. (°C).	Stability (% Initial)	
		Amoxicillin Trihydrate	Potassium Clavulanate
Initial		100	100
2	37	97	101
4	30	100	99
	37	98	99
8	20	101	98
	30	97	99
	37	96	100

EXAMPLE 7.

- 10 Tablets of the following composition were prepared: 10

Ingredient	mg/tablet
Amoxicillin Trihydrate	equivalent to 250 mg of pure non-hydrated amoxicillin
Potassium clavulanate	equivalent to 125 mg of pure clavulanic acid
Microcrystalline cellulose	250
Cross-linked polyvinylpyrrolidone	45
Magnesium Stearate	11.8
Glycine to	975

The preceding tablets were prepared as follows: The amoxicillin trihydrate and glycine were milled to fine powders on a suitable machine, the

potassium clavulanate was passed through a 30 mesh screen, all three materials were then blended with a portion of the magnesium stearate and compressed to a uniform density on a suitable tablet machine. The pressed slugs were milled to produce granules of a uniform size and density and the remainder of the ingredients were then added. The mix was blended and compressed to tablets on a suitable machine.

Fifteen of the above tablets were put into an amber glass bottle and the bottle closed by a screw cap. The storage properties of the composition is illustrated by the following:

Storage Period (months)	Storage Temp. (°C).	Stability (% Initial)	
		Amoxycillin Trihydrate	Potassium Clavulanate
Initial		100	100
2	37	100	98
4	30	99	97
	37	95	95

EXAMPLE 8.

Tablets of the following composition were prepared:

Ingredient	mg/tablet
Amoxycillin trihydrate	equivalent to 250 mg of pure non-hydrated amoxycillin
Potassium clavulanate	equivalent to 125 mg of pure clavulanic acid
Calcium Carbonate	175
Heavy Magnesium Carbonate	110
Cross-linked polyvinylpyrrolidone	75
Magnesium Stearate	19.5
Microcrystalline Cellulose to	1000

The preceding tablets were prepared as follows:

The amoxycillin trihydrate, potassium clavulanate and calcium carbonate were passed through a 30 mesh screen and then blended with microcrystalline cellulose and a proportion of the magnesium stearate. The mix was compressed to a uniform density on a suitable tablet machine and the pressed slugs then milled to produce granules of suitable size and density. The heavy magnesium carbonate was passed through a 30 mesh screen and then blended with the milled slugs, cross-linked PVP and the remainder of the magnesium stearate. The mix was compressed to tablets on a suitable machine.

Twenty five tablets as above were filled into a metal cannister, a sachet of molecular sieve added (1 g) and the cannister and contents stored. The results of this test were as follows:

Storage Period (Months)	Storage Temp. (°C)	Stability (% Initial)	
		Amoxycillin Trihydrate	Potassium Clavulanate
Initial		100	100
2	37	98	97
4	30	100	96
	37	97	94

EXAMPLE 9.

The tablets of Examples 7 and 8 were also produced in film coated form as follows:

The priming coat ingredients were added to an organic solvent (a dichloromethane/methanol mixture) and a high speed homogeniser used to disperse/dissolve the materials. The fine suspension thus obtained was sprayed from an atomizer nozzle onto a rotating bed of 2000—3000 tablets through which warm air is passed to remove the solvent. The rate of spraying was such that an even application of coat was achieved and the tablets did not adhere to each other. The top coat was then applied in the same manner. Details of suitable coating materials are given below:

Priming Coat Composition

Ingredients	mg/tablet (approx.)
Hydroxypropylmethyl cellulose film-formers	9.0
Ethyl cellulose	2.25
Diethyl Phthalate (plasticiser)	2.70
Titanium Dioxide (pigment)	4.0
	17.95

Top -- Coat (Type A)

Ingredients	mg/tablet (approx.)
Methacrylic acid -- methacrylate co-polymer	11.7
Diethyl Phthalate	2.3

Top -- Coat (Type B)

Ingredients	mg/tablet (approx.)
Opagloss (modified Shellac)	7.0

EXAMPLE 10.

Two part gelatin capsules may be filled with the ingredients specified in Example 6. The blend obtained immediately prior to final compression in to tablet form in Example 6 may be filled into capsules by hand or on a filling machine.

CLAIMS

1. A dry unit-dose pharmaceutical composition suitable for oral administration which composition comprises 20 mg to 1500 mg of amoxycillin trihydrate, 20 mg to 500 mg of potassium clavulanate and a pharmaceutically acceptable carrier with the proviso that the weight ratio of amoxycillin trihydrate to potassium clavulanate is from 6:1 to 1:1.
2. A composition as claimed in claim 1 wherein the ratio is from 3:1 to 2:1.
3. A composition as claimed in claim 1 which comprises from 80 mg to 600 mg of amoxycillin trihydrate and from 40 mg to 300 mg of potassium clavulanate with the proviso that the weight ratio of amoxycillin trihydrate to potassium clavulanate is 2:1.
4. A composition as claimed in any of claims 1—3 in the form of a shaped unit-dose.
5. A composition as claimed in claim 4 wherein the shaped unit-dose is a tablet.
6. A composition as claimed in claim 4 wherein the shaped unit-dose is a capsule.
7. A composition as claimed in any of claims 1—6 which comprises 250—300 mg of amoxycillin trihydrate.
8. A composition as claimed in any of claims 1—6 which comprises 125—150 mgs of amoxycillin trihydrate.
9. A packaged pharmaceutical composition of enhanced storage stability which comprises a

closed container containing one or more unit-dose compositions as claimed in any of claims 1—8 and a desiccant.

10. A packaged pharmaceutical composition as claimed in claim 9 wherein the container is reclosable by means of a screw-top.

5 11. A packaged pharmaceutical composition as claimed in claim 9 or 10 wherein the desiccant is silica gel. 5

12. A packaged pharmaceutical composition as claimed in claims 9 or 10 wherein the desiccant is crystalline sodium, potassium or calcium aluminosilicate.

10 13. A method of prolonging the storage life of a composition as claimed in any of claims 1—8 in a container which comprises storing said composition in an atmosphere maintained dry by the presence of a desiccant in the container. 10

14. A method as claimed in claim 13 wherein the desiccant is silica gel.

15. A method as claimed in claim 13 wherein the desiccant is crystalline sodium, potassium or calcium aluminosilicate.

15 16. A method as claimed in any of claims 13—15 wherein the container is reclosable by means of a screw-top. 15

17. A process for preparing a pharmaceutical composition as claimed in any of claims 1—8 which comprises bringing into association the components of said compositions.

Printed for Her Majesty's Stationary Office by the Courier Press, Leamington Spa, 1979. Published by the Patent Office,
25 Southampton Buildings, London, WC2A 1AY, from which copies may be obtained.

BEST AVAILABLE COPY